Abeona Therapeutics Inc Expected to Earn Q1 2024 Earnings of ($0.47) Per Share (NASDAQ:ABEO)

Abeona Therapeutics Inc (NASDAQ:ABEO) – Zacks Small Cap issued their Q1 2024 EPS estimates for shares of Abeona Therapeutics in a research report issued on Thursday, April 25th. Zacks Small Cap analyst D. Bautz forecasts that the biopharmaceutical company will post earnings of ($0.47) per share for the quarter. The consensus estimate for Abeona Therapeutics’ current full-year earnings is ($2.05) per share.

Several other analysts also recently commented on ABEO. StockNews.com downgraded shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, April 23rd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $36.00 price target on shares of Abeona Therapeutics in a research report on Tuesday, April 23rd.

Abeona Therapeutics Trading Up 2.2 %

Shares of NASDAQ:ABEO opened at $3.26 on Monday. The company has a market capitalization of $89.16 million, a PE ratio of -1.26 and a beta of 1.49. Abeona Therapeutics has a twelve month low of $2.83 and a twelve month high of $9.01. The firm has a 50 day simple moving average of $7.23 and a 200-day simple moving average of $5.62.

Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings data on Monday, March 18th. The biopharmaceutical company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.13).

Insider Activity at Abeona Therapeutics

In other news, SVP Brendan M. O’malley acquired 8,600 shares of the company’s stock in a transaction on Thursday, April 25th. The shares were bought at an average cost of $3.24 per share, with a total value of $27,864.00. Following the purchase, the senior vice president now owns 188,718 shares of the company’s stock, valued at approximately $611,446.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 5.30% of the stock is owned by insiders.

Hedge Funds Weigh In On Abeona Therapeutics

Institutional investors have recently bought and sold shares of the company. Simplex Trading LLC increased its stake in Abeona Therapeutics by 1,889.9% in the 3rd quarter. Simplex Trading LLC now owns 14,128 shares of the biopharmaceutical company’s stock valued at $59,000 after buying an additional 13,418 shares during the period. Jump Financial LLC acquired a new position in shares of Abeona Therapeutics during the 4th quarter worth $199,000. Schonfeld Strategic Advisors LLC acquired a new position in shares of Abeona Therapeutics during the 3rd quarter worth $648,000. Worth Venture Partners LLC grew its stake in shares of Abeona Therapeutics by 76.6% during the 3rd quarter. Worth Venture Partners LLC now owns 281,280 shares of the biopharmaceutical company’s stock worth $1,184,000 after purchasing an additional 121,969 shares during the period. Finally, Barclays PLC grew its stake in shares of Abeona Therapeutics by 100.0% during the 3rd quarter. Barclays PLC now owns 371,276 shares of the biopharmaceutical company’s stock worth $1,564,000 after purchasing an additional 185,638 shares during the period. 80.56% of the stock is owned by institutional investors and hedge funds.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.